Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cinacalcet for Symptomatic Hypercalcemia Caused by AP2S1 Mutations.

The New England journal of medicine - 7 Apr 2016

Howles Sarah A, Hannan Fadil M, Babinsky Valerie N, Rogers Angela, Gorvin Caroline M, Rust Nigel, Richardson Tristan, McKenna Malachi J, Nesbit M Andrew, Thakker Rajesh V

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Protein Complex 2
Share to Hypercalcemia
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 27050234
DOI: 10.1056/NEJMc1511646
PMCID: PMC4972445

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cinacalcet for Symptomatic Hypercalcemia Caused by AP2S1 Mutations.PMID 27050234Read ↗

Cinacalcet for management of hypercalcemia secondary to calcium-sensing receptor mutation.Semantic proximity Read ↗

Cinacalcet therapy in symptomatic 11-year-old girl with familial hypocalciuric hypercalcemia type 3.Semantic proximity Read ↗

Cinacalcet Treatment in an Adolescent With Concurrent 22q11.2 Deletion Syndrome and Familial Hypocalciuric Hypercalcemia Type 3 Caused byAP2S1MutationSemantic proximity Read ↗

Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3.Semantic proximity Read ↗

CDKN1B Mutation Analyses and Biochemical Characteristics in Patients with Symptomatic or asymptomatic Primary Hyperparathyroidism: A Prospective Single-Centre StudySemantic proximity Read ↗

Personalised medicines for familial hypercalcemia and hyperparathyroidism.Semantic proximity Read ↗

Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature.Semantic proximity Read ↗

Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?Semantic proximity Read ↗

Baricitinib treatment in children with COPA syndrome.Semantic proximity Read ↗

Case report: Non-PTH-dependent hypercalcemia in pregnancy: Consider CYP24A1 mutations.Semantic proximity Read ↗

Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1)Semantic proximity Read ↗

Ap2s1 mutation causes hypercalcaemia in mice and impairs interaction between calcium-sensing receptor and adaptor protein-2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.